Weinges K, Ehrhardt M, Nell G, Enzmann F
Diabetes Care. 1982 Nov-Dec;5 Suppl 2:67-70. doi: 10.2337/diacare.5.2.s67.
The study was concerned with the comparison of the action profile of regular and NPH preparations of human insulin (recombinant DNA) and of PPI (pork purified insulin). In addition, the action profiles of some mixtures (10:90, 15:85, 20:80, 25:75, 30:70) of regular and NPH human insulin were evaluated. The comparisons were based on the Gerritzen test. There was no statistically significant difference in the time-course of the blood glucose levels after administration of NPH human insulin and NPH PPI. A tendency was noted, however, that NPH human insulin has a faster onset of action and that the serum glucose minimum for NPH human insulin lasts longer. The serum glucose curves after the application of regular and NPH human insulin initially lie closer together than after the respective PPI preparations. In the later phase, regular human insulin interferes less with the NPH curves. This means that combinations of regular and NPH human insulin may have a clinically useful action profile. No skin reaction or other adverse reaction was detected after application of human insulin and no antibodies against human insulin and Escherichia coli protein were found.
该研究关注人胰岛素（重组DNA）常规制剂和NPH制剂以及猪纯化胰岛素（PPI）作用情况的比较。此外，还评估了常规人胰岛素与NPH人胰岛素的一些混合制剂（10:90、15:85、20:80、25:75、30:70）的作用情况。这些比较基于Gerritzen试验。注射NPH人胰岛素和NPH PPI后，血糖水平的时间进程没有统计学上的显著差异。然而，注意到一种趋势，即NPH人胰岛素起效更快，且NPH人胰岛素的血清葡萄糖最低值持续时间更长。应用常规人胰岛素和NPH人胰岛素后的血清葡萄糖曲线最初比应用各自的PPI制剂后靠得更近。在后期，常规人胰岛素对NPH曲线的干扰较小。这意味着常规人胰岛素与NPH人胰岛素的组合可能具有临床上有用的作用情况。应用人胰岛素后未检测到皮肤反应或其他不良反应，也未发现抗人胰岛素和大肠杆菌蛋白的抗体。
